Fig. 1: MTHFD2 localizes on chromatin in cancer cells.
From: Nuclear localization of MTHFD2 is required for correct mitosis progression
a Comparison between Transcripts per Million (TPM) expression values of MTHFD2 in healthy and tumor tissues; paired two-tailed Wilcoxon test (n indicates the number of patients with paired samples for each cancer type). BLDA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma. b Western blot of cytosolic (cyt) and chromatin (chr) fractions after subcellular fractionation in a panel of cancer cell lines. Vinculin, Histone H3 and FDX1 are used as cytosolic, nuclear and mitochondrial markers, respectively. c Immunofluorescence of MTHFD2 in MCF7 (up), H358 (middle) and HCT116 (down) cells. MTHFD2 is shown in green (left) or royal (right) and DAPI in gray; confocal mode, scale bar 10 μm. d MTHFD2 and DAPI mean +/- s.d. intensity line profiles of the cell diameter of the respective cell lines, along with their corresponding backgrounds (n indicates number of individual cells).
